Pathogenesis and how it relates to drug Phenotypes and assessment of psoriasis and psoriatic arthritis Pustular psoriasis Comorbidities: Focus on metabolic syndrome and mental health Optimizing the use of topicals and standard systemics Optimizing the use of biologics Challenging cases workshop: An integrated learning experience Paradoxical reactions to biologics Comprehensive management of psoriasis
What did we learn? Reflections on challenging cases workshop from day 1 Challenging cases workshop - presented by delegates Ambition in psoriasis - Striving for more
OPENING COMMENTS Novartis introduction and overview of program Welcome and introduction to the International Psoriasis Council
PATHOPHYSIOLOGY OF PSORIASIS – ROLE OF CYTOKINES AND POTENTIAL TARGETS Evolution of understanding of the cytokines; role of IL-13 and TNFi; differential role of IL-17
OVERVIEW OF PSORIASIS AND COMORBIDITIES Epidemiology of plaque psoriasis
THE CLINICAL SPECTRUM OF PSORIASIS Screening and assessment, pros and cons and assessment tool, emphasis on PASI
TREATMENT GOALS Evolution of management from PASI 75 to PASI 100
NON-BIOLOGIC SYSTEMIC AGENTS Methotrexate, cyclosporine, apremilast and others
BIOLOGICS IN PSORIASIS
MONITORING AND MAINTENANCE OF RESPONSE Follow up of the patient; lab and clinical parameters
CHALLENGES IN THE LONG TERM MANAGEMENT OF PSORIASIS Long term efficacy of biologics; reduction/loss of response over a period of time; how to approach such a patient and manage
CHALLENGING CASES: IPC MASTERCLASS 1.0 EXPERIENCES
COMPLEXITIES OF DIAGNOSIS AND TREATMENT - BREAK OUT SESSIONS
Challenging Cases: presented by the faculty
NEW TREATMENT PARADIGMS IN THE MANAGEMENT OF PSORIASIS Role of PDE-4i and P19 as a target
TREATING BEYOND THE SKIN Focus on psoriatic arthritis: Risk factors, screening and diagnosis
LUNCH
Managing comorbidities and psoriasis in special populations - BREAK OUT SESSIONSTopic 1: Children Topic 2: Women Topic 3: Comorbidities
1ª Módulo
Timezones: Guatemala City/San Jose: 12:00 pm - 2:00 pm Bogota/Mexico City: 1:00 pm - 3:00 pm Santiago/Asunción: 2:00 pm - 4:00 pm Buenos Aires/São Paulo: 3:00 pm - 5:00 pm
Introducciones Claudia de la Cruz
Actualizaciones en Fisiopatología Matías Maskin Global Psoriasis Atlas (GPA) y Epidemiologia en LATAM Chris Griffiths Severidad en Psoriasis: Categorías Peter van de Kerkhof Metas de tratamiento, Target to treat Cristina Echeverría
Discusión
2º Módulo
3º Módulo
4º Módulo
Actualización en Terapias Biológicas: bloqueadores Anti TNF alfa Claudia de la Cruz Actualización en Terapias Biológicas: Biosimilares Cristina Echeverría
Actualización en Terapias Biológicas: Inhibidores de IL17 Enrique Rivas Inhibidores de Il12 y 23 Matías Maskin
5º Módulo
Actualización en Terapias Biológicas: lo nuevo (inhibidores de IL36) César González Psoriasis y salud mental Karina Malvido Psoriasis y Covid I: Cómo afecta la pandemia a nuestros pacientes Claudia de la Cruz Psoriasis y Covid II: VACUNAS en latam Juan Bravo Ojeda Discusión Mesa redonda: Cómo escoger el Tratamiento adecuado para mi paciente Claudia de la Cruz, Cristina Echeverría, César González, Karina Malvido, Juan Bravo Ojeda
Mahira Hamdy El Sayed, MSc, MD
Christopher EM Griffiths, OBE, MD, FRCP, FMedSci
Mohamed El-Komy, MD
Ahmed Nassar, Ain Shams University
Miriam Samir, Ain Shams University
Aya AlOrbani, Cairo University
Peter van de Kerkhof, MD, PhD
Nejib Doss, MD
Faculty
Christopher EM Griffiths, OBE, MD, FRCP, FMedSci, moderator Mahira Hamdy El Sayed, MSc, MD, Omid Zargari, MD, FAAD, panelists
Peter van de Kerkhof, MD, PhD, moderator Mahira Hamdy El Sayed, MSc, MD, panelist
Asma Ghanem Bashir, Libya Moneer Omran Bugrein, Libya Sahar Dadkhahfar, Iran Manal Elmubarak, Sudan Mostafa Khalaf, Egypt Alia Ramadan, Egypt
Mahira Hamdy El Sayed, MSc, MD, moderator
In the latest Psoriasis Review IPC's monthly review of the latest news in the field of psoriasis. Read the latest issue Latest news New IPC CouncilorJune 16, 2022Dr. Claus Johansen joins the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world. PsoProtect Registry Data UpdateJune 15, 2022PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Commentary: Biomarkers of Disease Progression in Psoriasis: Current State-of-the-ArtJune 13, 2022In personalized care for patients, psoriasis biomarkers will be highly relevant. At present, various centers have investigated biomarkers and their clinical significance for psoriasis progression. Read commentary from Andrea Chiricozzi, MD, on three recent publications. Arcutis Biotherapeutics, Inc. Announced Findings From the Skin Insights: Uncovering Psoriasis SurveyJune 02, 2022Arcutis Biotherapeutics, Inc. shared their finding from the Skin Insights: Uncovering Psoriasis Survey. More News